FIRE Funds Income Target ETF FIRI 深 沪
等待开盘 07-02 09:30:00 美东时间
18.9449
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 18.9449
- 总市值 123.14万
- 52周最高 19.115
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 17.6612
- 委 比 0.00%
- 总股本 6.50万
- 历史最高 18.1637
- 量 比 0
- 振 幅 0.00%
- 历史最低 17.7417
- 每 手 1
- 风险率 0.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多As Supreme Court's term nears its end, three major Trump rulings due
As Supreme Court's term nears its end, three major Trump rulings due Justices consider Trump's move to fire Fed and FTC officials Ruling due on Trump order limiting birthright citizenship Decisions loom on mail-in ballots, campaign finance limits Legality of transgender athletes crackdown to be deci
06-28 18:00
LIVE MARKETS-Nasdaq extends recent slide, but Micron shares pop
LIVE MARKETS-Nasdaq extends recent slide, but Micron shares pop Dow up >1%, S&P 500 also higher; Nadaq red Industrials lead S&P 500 sector gainers; commun. services down the most STOXX index up 1% Gold, US crude oil up; dollar, bitcoin down US 10-year Treasury yield falls to ~4.37% Welcome to the ho
06-25 22:31
LIVE MARKETS-Solid data boosts stock futures
LIVE MARKETS-Solid data boosts stock futures US stock index futures higher STOXX index up 0.9% Dollar flat; gold, bitcoin up US crude slides ~1% US 10-year Treasury yield falls to ~4.37% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your tho
06-25 21:06
Aevex wins $15.2 million option year on California FIRIS aerial intelligence contract
Aevex wins $15.2 million option year on California FIRIS aerial intelligence contract Aevex won a USD 15.2 million option-year award to continue supporting California’s FIRIS aerial intelligence contract for Cal OES. Work covers real-time airborne intelligence for emergency readiness, with a focus o
06-23 18:00
AIM ImmunoTech Reports Positive Phase 2 DURIPANC Update As Final Patient Enrolled In Pancreatic Cancer Trial
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported positive progress in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen® (rintatolimod) combined with
06-08 20:36
Actuate Therapeutics Features Post-Hoc Efficacy And Biomarker Analyses From Randomized Phase 2 Study, Along With Clinical Data From Phase 2 Study Of Elraglusib In Combination With FFX And TGF-Β Inhibitor Losartan In mPDAC Patients, At 2026 ASCO
- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone- Patients with P53WT genomics
06-01 19:07
Cardiff Oncology Reveals Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib In First-Line RAS-Mutated mCRC
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that it will host an investor webcast featuring members of
05-22 05:06
Oncolytics Biotech Announces Its Data From REO 022 Trial In Metastatic Colorectal Cancer Shows 19.5-Month Median Duration Of Response In Second-Line KRAS-Mutant MSS mCRC Participants
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to activate innate
05-04 21:02
Cardiff Oncology To Present Updated Data From CRDF-004 In Participants With First-Line RAS-Mutated Metastatic Colorectal Cancer At 2026 American Society Of Clinical Oncology
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced it will present updated data from CRDF-004, a randomized
04-21 22:06
Caris Life Sciences Launches AI-Driven Pancreatic Cancer Signature To Guide First-Line Treatment In Pancreatic Ductal Adenocarcinoma
Caris AI Insights are proprietary and only available to Caris Life Sciences customersIRVING, Texas, March 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric,
03-09 20:39
